Renal Failure News and Research

RSS

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.

Research reveals new biological function of polycystins in regulating pressure sensing

What is the role of proteins called polycystins in patients with polycystic kidney disease? A team of researchers from CNRS and INSERM, led by Eric Honoré from the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC, Université de Nice Sophia Antipolis/CNRS) has elucidated the molecular and cellular mechanisms linked to polycystin malfunctions that cause this common hereditary disease.

6 Nov 2009

Endothelin increases T cells in the kidneys leading to renal injury

A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both.

6 Nov 2009

Average cost of patient deaths much higher than patients who were discharged alive

One of every three people who died in 2007 in the United States were in the hospital for treatment at the time of their deaths, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The cost of their hospital stays was about $20 billion.

6 Nov 2009

Third quarter 2009 financial results announced by Affymax

Affymax, Inc. today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

New FDA-approved heart pump for high-risk patients

Cardiologists at the University of Illinois Medical Center are using a new heart pump that can be inserted without the need for surgery and allows them to treat high-risk patients with a procedure to unblock their heart arteries.

4 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.

3 Nov 2009

FDA updates Byetta prescribing information following reports of kidney problems

The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.

3 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Lupus patients rarely develop kidney disorders after a kidney transplant

Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Group education is an effective way to help alleviate organ shortage and increase living donations

Get-togethers with a kidney disease patient's family and friends can improve their willingness to consider donation, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

Kidney transplant consent forms are often written at a level that makes it difficult for many kidney patients to fully understand them, according to a paper being presented at the American Society of Nephrology's annual meeting in San Diego, CA. The study findings indicate that consent forms are written on average at a 12th-grade reading level, but to ensure all patients fully comprehend treatment options should be prepared at a 5th - 8th grade reading level.

30 Oct 2009

Anabolic steroids may cause severe kidney dysfunction

Athletes who use anabolic steroids may gain muscle mass and strength, but they can also destroy their kidney function, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Renal Failure News and Research

Further Reading

Research reveals new biological function of polycystins in regulating pressure sensing

Endothelin increases T cells in the kidneys leading to renal injury

Average cost of patient deaths much higher than patients who were discharged alive

Third quarter 2009 financial results announced by Affymax

Safeguard Scientifics reports financial results for the third quarter of 2009

New FDA-approved heart pump for high-risk patients

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA updates Byetta prescribing information following reports of kidney problems

Gilead Sciences to present Viread Phase III clinical trial data

Lupus patients rarely develop kidney disorders after a kidney transplant

Combination of inhibitor and antioxidants may help prevent diabetes complications

Amgen publishes Phase 3 study results of Aranesp

Data from multiple clinical and preclinical studies evaluating Hematide announced

Group education is an effective way to help alleviate organ shortage and increase living donations

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

Anabolic steroids may cause severe kidney dysfunction

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

Roche discloses the results of first Phase III clinical study using Taspoglutide

Shire receives European approval for FOSRENOL

Free guide - Everything about renal proximal tubule cells eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News